Pianpian Chen

Pianpian represents emerging companies, public companies and venture capital funds. She advises clients on matters including Hong Kong initial public offerings (IPOs) and other equity capital markets transactions, as well as compliance with Hong Kong Listing Rules and securities regulations.

Deals that Pianpian has worked on include:

IPOs – biopharmaceuticals, medical devices and healthcare

• Represented Chapter 18A-listed Diagens Biotechnology (2526.HK), the first medical imaging artificial intelligence model company successfully listed in Hong Kong*
• Represented Chapter 18A-listed Suzhou Basecare (2170.HK), an innovative platform of genetic testing solutions for assisted reproduction in China*
• Represented Chapter 18A-listed Ocumension Therapeutics (1477.HK), an ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies*
• Represented Chapter 18A-listed Ascletis Pharma (1672.HK), the first biotechnology company successfully listed in Hong Kong since the Hong Kong Stock Exchange’s new rules took effect on April 30, 2018, opening the door to pre-revenue biotechnology companies*
• Represented Morgan Stanley and CICC as the joint sponsors and underwriters on the IPO for ImmuneOnco Biopharmaceuticals (Shanghai) (1541.HK), a leading science-driven biotechnology company dedicated to the development of immuno-oncology therapies in China*
• Represented Morgan Stanley, CICC and Huatai International as the joint sponsors and underwriters on the IPO for Keymed Biosciences (2162.HK), a biotechnology company focusing on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas*
• Represented Crown Bioscience International (TWO: 6554), a global contract research organization headquartered in California providing discovery and preclinical and translational platforms and services to advance oncology and immuno-oncology, as local counsel in its IPO on the Taipei Exchange*

IPOs – consumer, technology, media, and telecommunications (TMT), and others

• Represented Quzhi Group (0917.HK) in its IPO and listing in Hong Kong*
• Represented Zhongxu Future (9890.HK) in its IPO and listing in Hong Kong*
• Represented Joy Spreader Group (6988.HK) in its IPO and listing in Hong Kong*
• Represented Finger Joy (6860.HK) in its IPO and listing in Hong Kong*
• Represented China Merchants Securities and CSC Financial as joint sponsors and other underwriters in the IPO and listing of Strawbear Entertainment (2125.HK) in Hong Kong*
• Represented CITIC Securities and CSC Financial as sole sponsors and other underwriters in the IPO and listing of Doumeng Technology (1917.HK) in Hong Kong*
• Represented Quanzhou Huixin Microfinance (1577.HK) in its listing in Hong Kong*
• Represented Guotai Junan Securities as sole sponsor and other underwriters in the IPO and listing of Juzhu Construction (1459.HK) in Hong Kong*

Hong Kong-listed company regulatory compliance advisory

• Represented Quanzhou Huixin Micro-credit (1577.HK), a microfinance company in China*

Others

• Represented CMB International Capital as the sole global coordinator and placing agent in the H-share placement of Bank of Jinzhou

* Matter handled before joining Cooley

Before joining Cooley, Pianpian worked as associate for another global law firm in Beijing.